Major histocompatibility complex Class II-based therapy for stroke

Bella M. Gonzales-Portillo, Jea-Young Lee, Arthur A. Vandenbark, Halina Offner, Cesario V. Borlongan

Abstract:
This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.

Keywords: Cell death, cytokines, DRmQ, mesenchymal stem cell, mitochondrial transfer, stem cell therapy

Expanding Immune Response

Stroke continues to be one of the leading causes of death around the world, and neuroinflammation remains a primary cause of the secondary cell death that occurs after an ischemic event.[3,4] It is more difficult to develop a stroke treatment due to the limited therapeutic window that accompanies a stroke.[5-7] Many therapeutic treatments aim at improving the immune response, specifically weakening neuroinflammation.[8,9] Stroke is associated with both central and peripheral inflammatory responses, and the spleen contributes a major role in secondary cell death.[10] Partial major histocompatibility complex (MHC) Class II constructs can limit early immune response, therefore, sequestering ischemic-induced inflammation.[11,12] MHC Class II constructs are a viable stroke treatment because of their neuroantigen-specific modulation of T-cells as well as CD74 signaling.[11,12,15]

Major Histocompatibility Complex Class II Constructs

MHC Class II constructs can potentially mitigate cell death in traumatic brain injury (TBI) and stroke.[12] DRhQ and DRmQ represent advanced MHC Class II constructs that have shown safety and efficacy in preclinical models of TBI and stroke. DRhQ was created for clinical development while DRmQ was designed as a preclinical therapeutic for demonstrating proof-of-concept efficacy in animal models of autoimmune encephalomyelitis.[13-15] Using Stroke Therapy Academic Industry Roundtable (STAIR) guidelines, we tested DRmQ in a stroke model in rats.[16] Two different species of stroke model were used to analyze the clinical importance of MHC Class II constructs. That study observed the anti-inflammatory effects of DRmQ in rat stroke models using behavioral and histological assays.[17]

How to cite this article: Gonzales-Portillo BM, Lee JY, Vandenbark AA, Offner H, Borlongan CV. Major histocompatibility complex Class II-based therapy for stroke. Brain Circ 2021;7:37-40.
Major Histocompatibility Complex Class II constructs as Stroke Therapeutics

A potent stroke treatment entails the inhibition of neuroantigen-specific T-cells, cytotoxic monocytes, and macrophages, a combination which could provide potential therapeutic benefits to stroke patients. Indeed, attenuation of histological and behavioral deficits was seen in stroke animals that were administered partial MHC Class II constructs subcutaneously.\[17\] Adult Sprague-Dawley rats that had been exposed to a stroke model and a mouse partial MHC Class II construct (i.e., DRmQ) were analyzed.\[17\] A decrease in stroke-induced motor deficits, neuroinflammation, infarcts, and peri-infarct cell loss was observed.\[17\] Tumor necrosis factor (TNF)-α and interleukin-6 upregulation was also altered in the spleen of DRmQ-treated stroke animals providing further evidence of potential regulation of peripheral inflammation by MHC Class II constructs.\[17\] These results suggest that the use of partial MHC Class II constructs as a viable treatment for stroke may halt central and peripheral inflammation responses reducing the neuroinflammation that results in secondary cell death after stroke [Figure 1].

Behavioral Improvements in DRmQ-Treated Stroke Animals

Several behavioral tests were conducted to compare the motor skills in the DRmQ-treated mice and the mice that were not treated with DRmQ.\[17\] The DRmQ-treated group showed improved features in all of the motor tests that were administered. The DRmQ-treated animals also featured a smaller cerebral infarct area and improved cell survival when compared to the control mice.\[17\] Reduced proinflammatory cytokines in the peri-infarct area were also observed. Finally, the spleen was analyzed to determine the effects of DRmQ on peripheral inflammatory response. Results showed a higher spleen weight in DRmQ-treated stroke animals suggesting a suppression of the splenic inflammatory response and reduced splenic atrophy.\[17\]

Normalized Inflammatory Responses in DRmQ-Treated Stroke Animals

DRmQ treatment was seen to improve stroke-induced inflammatory markers.\[17\] There was a large decrease in the expression of the proinflammatory cytokine TNF-α and Ionized calcium-binding adaptor protein-1-activated microglia in the brain. This decrease in microglia activation and proinflammatory cytokines potentially reflects the ability of DRmQ to reduce secondary cell death in stroke.\[17\] DRmQ was also observed to reduce inflammation and splenic atrophy in the spleen. Overall, these results demonstrate DRmQ’s ability to suppress the inflammatory response by reducing proinflammatory cytokines.

Since neuroinflammation is a primary cause of secondary cell death in stroke, targeting inflammation is essential when developing treatments for stroke.\[10,11,13,18-22\] MHC Class II constructs regulate the immune response in stroke and other neurovascular diseases.\[10,12,15\] In stroke, treatment with a MHC Class II construct decreased the infarct size in both genders of mice after middle cerebral artery occlusion (MCAO) by inhibiting activated microglia and infiltrating monocytes.\[8\] MHC Class II construct administration also displayed similar results in the distal MCAO stroke model by decreasing infarct size and reducing proinflammatory cytokines.\[8,12,23\]

Anti-Neuroinflammation-Based Treatments

Parallel studies demonstrating the potential of anti-neuroinflammation-based treatments, along the lines of producing similar therapeutic effects as MHC Class II constructs, can be appreciated in mesenchymal stem cell (MSC) transplantation and mitochondrial transfer, as discussed below.

Stem Cell Therapy

MSCs are multipotent stem cells located in the bone marrow alongside connective tissue.\[24-26\] MSCs are very easily obtained and manipulated which makes them an appealing cell source for the treatment of stroke.\[27-29\] Allogeneic MSCs from a donor can be
transplanted without the need for immunosuppression. These characteristics of MSCs make them a viable candidate for ischemic stroke treatments. Similar to the neurotherapeutic effects produced by MHC Class II constructs in suppressing stroke-induced inflammation, stem cell therapy has the ability to reduce the deleterious inflammatory responses that follow ischemic events.

**Mitochondrial Transfer**

Following an ischemic event, one secondary cell death event that contributes to neuroinflammation is the lack of adenosine triphosphate and nutrients, which indicates the importance of the role of mitochondria in stroke pathology. The penumbral neurovascular unit degenerates rapidly due to mitochondrial dysfunction and inflammation requiring an effective treatment for stroke. Mitochondrial transfer via stem cell transplantation has been shown as a viable option in restoring mitochondrial function after stroke. Notably, stem cell-mediated mitochondria transfers promote cell survival coincident with dampened inflammation in stroke animals, thus serving as an effective strategy in reducing detrimental inflammation in ischemic stroke.

**Conclusion**

This review discusses the therapeutic effects of DRmQ following STAIR criteria as well as providing evidence to support the importance of the peripheral component in stroke treatment and pathology. DRmQ improved peripheral inflammation from the spleen which is a critical therapeutic target in neuroprotection during ischemia. The ability of DRmQ to modulate the central and peripheral inflammatory response contributes to its potential therapeutic effects in treating stroke.

Further research needs to determine whether the therapeutic effects of DRmQ could extend into the chronic phase of stroke. Although no harmful effects were observed from DRmQ treatment, it is important to remain cautious of any adverse effects when testing the long-term effect of DRmQ. Correct dosage and administration information also needs to be researched to optimize the effects of the treatment.

Similar anti-neuroinflammation-based treatments, such as stem cell therapy and mitochondrial transfer, resemble the therapeutic benefits of MHC Class II constructs in dampening inflammation after stroke. Altogether, these preclinical data advance the use of targeting inflammation as a potential treatment for stroke and other neurological disorders characterized by a harmful inflammatory response.

**Acknowledgment**

All figures were created with Biorender.com.

**Financial support and sponsorship**

Biomedical Laboratory Research and Development Merit Review Award 2101 BX000226 (AAV), Senior Research Career Scientist Award 1IK6BX004209 (AAV), the National Institute of Allergy and Infectious Diseases award 2R42AI122574 (AAV), and the NIH R21AI148409 award (HO).

**Conflicts of interest**

Prof. Cesario V. Borlongan is Associate Editor of *Brain Circulation.*

**References**

1. Nishino H, Borlongan CV. Restoration of function by neural transplantation in the ischemic brain. Prog Brain Res 2000;127:461-76.
2. Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu SJ, et al. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Prog Neurobiol 2008;85:318-34.
3. Borlongan CV. Cell therapy for stroke: Remaining issues to address before embarking on clinical trials. Stroke 2009;40:S146-8.
4. Blecharz-Lang KG, Wagner J, Fries A, Nieminen-Kelhät M, Rösner J, Schneider UC, et al. Interleukin 6-mediated endothelial barrier disturbances can be attenuated by blockade of the IL6 receptor expressed in brain microvascular endothelial cells. Transl Stroke Res 2018;9:631-42.
5. Simon R, Meller R, Yang T, Pearson A, Wilson G. Enhancing base excision repair of mitochondrial DNA to reduce ischemic injury following reperfusion. Transl Stroke Res 2019;10:664-71.
6. Navarro-Oviedo M, Roncal C, Salicio A, Belzunce M, Rabal O, Toledo E, et al. MMP10 promotes efficient thrombolysis after ischemic stroke in mice with induced diabetes. Transl Stroke Res 2018;10:389-401.
7. Griemert EV, Recarte Pelz K, Engelhard K, Schäfer MK, Thal SC. PAI-1 but not PAI-2 gene deficiency attenuates ischemic brain injury after experimental stroke. Transl Stroke Res 2018;10:372-80.
8. Benedek G, Vandenbark AA, Alkayed NJ, Offner H. Partial MHC Class II constructs as novel immunomodulatory therapy for stroke. Neurochem Int 2017;107:138-47.
9. Tan Q, Guo P, Zhou J, Zhang J, Zhang B, Lan C, et al. Targeting neutrophil extracellular traps enhanced tPA fibrinolysis for experimental intracerebral hemorrhage. Transl Res 2019;211:139-146.
10. Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, et al. DRxR1-MOG-55 reduces permanent ischemic brain injury. Metab Brain Dis 2017;32:1395-402.
11. Dotson AL, Chen Y, Zhu W, Libal N, Alkayed NJ, Offner H. Partial MHC constructs treat thromboembolic ischemic stroke characterized by early immune expansion. Transl Stroke Res 2016;7:70-8.
12. Vandenbark AA, Meza-Romero R, Benedek G, Offner H. A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. J Neuroinflammation 2019;16:14.
13. Wang J, Ye Q, Xu J, Benedek G, Zhang H, Yang Y, et al. DRxR1-MOG-55 reduces permanent ischemic brain injury. Transl Stroke Res 2017;8:284-93.
14. Meza-Romero R, Benedek G, Gersner G, Kent G, Nguyen H, Offner H, et al. Increased CD74 binding and EAE treatment
efficacy of a modified DRα1 molecular construct. Metab Brain Dis 2019;34:153-64.
15. Benedek G, Zhu W, Libal N, Casper A, Yu X, Meza-Romero R, et al. A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke. Metab Brain Dis 2014;29:37-45.
16. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M; STAIR VI Consortium. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009;40:2594-600.
17. Lee JY, Castelli V, Bonsack B, Coats AB, Navarro-Torres L, Garcia-Sánchez J, et al. A novel partial MHC Class II construct, DRmQ, inhibits central and peripheral inflammatory responses to promote neuroprotection in experimental stroke. Transl Stroke Res 2020;11:831-6.
18. Zhu W, Libal NL, Casper A, Bodhankar S, Offner H, Alkayed NJ. Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke. Transl Stroke Res 2014;5:612-7.
19. Xu K, Lee JY, Kaneko Y, Tuazon JP, Vale F, van Loveren H, et al. Human stem cells transplanted into the rat stroke brain migrate to the spleen via lymphatic and inflammation pathways. Haematologica 2019;104:1062-73.
20. Pan J, Palmateer J, Schallert T, Hart M, Pandya A, Vandenbark AA, et al. Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke. Transl Stroke Res 2014;5:577-85.
21. Seifert HA, Offner H. The splenic response to stroke: From rodents to stroke subjects. J Neuroinflammation 2018;15:195.
22. Seifert HA, Benedek G, Nguyen H, Gerstner G, Zhang Y, Kent G, et al. Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells. Metab Brain Dis 2018;33:1599-607.
23. Zhu W, Casper A, Libal NL, Murphy SJ, Bodhankar S, Offner H, et al. Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res 2015;6:60-8.
24. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9-20.
25. Walczak P, Zhang J, Gilad AA, Kedzirek DA, Ruiz-Cabello J, Young RG, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008;39:1569-74.
26. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006;36:2566-73.
27. Ishikawa H, Tajiri N, Shinozuka K, Vasconcellos J, Kaneko Y, Lee HJ, et al. Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation. Stroke 2013;44:3473-81.
28. Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Cerebral ischemia and CNS transplantation: Differential effects of grafted fetal rat striatal cells and human neurons derived from a clonal cell line. Neuroreport 1998;9:3703-9.
29. Bhata R, Hare JM. Mesenchymal stem cells: Future source for reparative medicine. Congest Heart Fail 2005;11:87-91.
30. Watanabe M, Yavagal DR. Intra-arterial delivery of mesenchymal stem cells. Brain Circ 2016;2:114-7.
31. Liu X, Ye R, Yan T, Yu SP, Wei L, Xu G, et al. Cell based therapies for ischemic stroke: From basic science to bedside. Prog Neurobiol 2014;115:92-115.
32. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001;189:49-57.
33. Blum A, Balkan W, Hare JM. Advances in cell-based therapy for peripheral vascular disease. Atherosclerosis 2012;223:269-77.
34. Russo E, Nguyen H, Lippert T, Tuazon J, Borlongan CV, Napoli E. Mitochondrial targeting as a novel therapy for stroke. Brain Circ 2018;4:84-94.
35. Nguyen H, Zarriello S, Coats A, Nelson C, Kingsbury C, Gorsky A, et al. Stem cell therapy for neurological disorders: A focus on aging. Neurobiol Dis 2019;126:85-104.
36. Stoneseifer C, Corey S, Ghanevar S, Diamanidis Z, Acosta SA, Borlongan CV. Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. Prog Neurobiol 2017;158:94-131.